YU14002A - Mezoprogestini (progesteron receptor modulatori) za lečenje i prevenciju benignih hormonskih ginekoloških poremećaja - Google Patents

Mezoprogestini (progesteron receptor modulatori) za lečenje i prevenciju benignih hormonskih ginekoloških poremećaja

Info

Publication number
YU14002A
YU14002A YU14002A YUP14002A YU14002A YU 14002 A YU14002 A YU 14002A YU 14002 A YU14002 A YU 14002A YU P14002 A YUP14002 A YU P14002A YU 14002 A YU14002 A YU 14002A
Authority
YU
Yugoslavia
Prior art keywords
prevention
treatment
mesoprogestins
disorders
progesterone receptor
Prior art date
Application number
YU14002A
Other languages
English (en)
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Jenapharm Gmbh. & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh. & Co.Kg. filed Critical Jenapharm Gmbh. & Co.Kg.
Publication of YU14002A publication Critical patent/YU14002A/sh
Publication of RS50283B publication Critical patent/RS50283B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Ovaj pronalazak obuhvata upotrebu mezoprogestina, nove klase progesteron receptor modulatora (PRM), za lecenje i prevenciju benignih hormonskih ginekoloskih poremecaja: a) za lecenje ginekoloskih poremecaja kao sto su endometritis, fibroidi materice, post operativne peritonalne priraslice, disfunkcionalna krvavljenja (metroragija, menoragija) i dismenoreja; b) za prevenciju ginekoloskih poremecaja kao sto su post operativne peritonalne priraslice, disfunkcionalna krvavljenja (metroragija, menoragija) i dismenoreja; c) postupak za lecenje i prevenciju gore navedenih poremecaja kod zenki, pozeljno kod zena, kojima je potrebno lecenje ili prevencija jednog ili vise od ovih poremecaja, sa efikasnom koliclnom mezoprogestina. Mezoprogestini su definisani kao jedinjenja koja poseduju i agonisticne i antagonisticne aktivnosti na progesteron receptor (PR) in vivo. Oni stabilizuju funkciju PR na srednjem nivou agonista i antagonista. Odgovarajuca funkcionalna stanja se ne mogu ostvariti progestinima ili antiprogestinima. Dnevna doza mezoprogestina je 0,5 do 100 mg, pozeljno 5 do 50 mg, a najpozeljnije 10 do 25 mg. J867, J912, J956 i J1042 su mezoprogestini pozeljni prema ovom pronalasku.
YUP-140/02A 1999-08-31 2000-08-31 Mezoprogestini za lečenje i prevenciju benignih ginekoloških poremećaja RS50283B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38614199A 1999-08-31 1999-08-31

Publications (2)

Publication Number Publication Date
YU14002A true YU14002A (sh) 2006-01-16
RS50283B RS50283B (sr) 2009-09-08

Family

ID=23524338

Country Status (34)

Country Link
EP (1) EP1229906B1 (sh)
JP (1) JP2003535029A (sh)
KR (3) KR20080066095A (sh)
AR (1) AR025457A1 (sh)
AT (1) ATE375160T1 (sh)
AU (1) AU781840B2 (sh)
BG (1) BG65817B1 (sh)
BR (1) BR0014161A (sh)
CA (1) CA2382580C (sh)
CO (1) CO5200772A1 (sh)
CZ (1) CZ2002704A3 (sh)
DE (1) DE60036723T2 (sh)
DK (1) DK1229906T3 (sh)
EA (1) EA007854B1 (sh)
EE (1) EE05172B1 (sh)
ES (1) ES2295050T3 (sh)
HR (1) HRP20020267A2 (sh)
HU (1) HUP0202429A3 (sh)
IL (1) IL148416A0 (sh)
LT (1) LT5034B (sh)
LV (1) LV12941B (sh)
ME (1) MEP13808A (sh)
MX (1) MXPA02002191A (sh)
NO (1) NO20020999L (sh)
NZ (1) NZ517471A (sh)
PE (1) PE20010578A1 (sh)
PL (1) PL198790B1 (sh)
PT (1) PT1229906E (sh)
RO (1) RO122179B1 (sh)
RS (1) RS50283B (sh)
SI (1) SI20852B (sh)
SK (1) SK287192B6 (sh)
UA (1) UA78184C2 (sh)
WO (1) WO2001015679A2 (sh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
AU2003255355A1 (en) * 2002-08-02 2004-02-25 Schering Aktiengesellschaft Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
JP4709328B2 (ja) * 2009-06-17 2011-06-22 国立大学法人 熊本大学 月経困難症の予防及び／又は治療薬
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
CA3152099A1 (en) * 2019-09-23 2021-04-01 Liang Liang Methods of treatments to prolong gestation and complications of menstruation or gestation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633244A1 (de) 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
CZ176197A3 (cs) * 1994-12-22 1998-09-16 Ligand Pharmaceuticals Incorporated Modulátory steroidových receptorů a způsoby jejich přípravy a použití
US5688810A (en) * 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
MX9603889A (es) 1995-02-02 1997-04-30 Schering Ag Antagonistas de progesterona para la produccion de agente farmaceuticos para el tratamiento de sangrado uterino disfuncional.
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
JP4260886B2 (ja) * 1996-05-01 2009-04-30 アメリカ合衆国 新規の抗プロゲステロンとしての２１―置換プロゲステロン誘導体
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
BR9916999A (pt) * 1999-01-14 2001-10-30 Bayer Ag Heterociclos de 2-arilimino substituìdos ecomposições contendo-os, para uso como agentesde ligação do receptor de progesterona
CA2371273A1 (en) * 1999-05-04 2000-11-09 Andrew Fensome Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
EA007854B1 (ru) 2007-02-27
WO2001015679A3 (en) 2001-11-22
SK2992002A3 (en) 2002-07-02
IL148416A0 (en) 2002-09-12
ES2295050T3 (es) 2008-04-16
ATE375160T1 (de) 2007-10-15
PL198790B1 (pl) 2008-07-31
KR20020027616A (ko) 2002-04-13
HUP0202429A3 (en) 2004-04-28
AU781840B2 (en) 2005-06-16
UA78184C2 (en) 2007-03-15
RS50283B (sr) 2009-09-08
CA2382580A1 (en) 2001-03-08
HUP0202429A2 (en) 2002-10-28
NZ517471A (en) 2004-02-27
CO5200772A1 (es) 2002-09-27
LV12941B (en) 2003-06-20
LT2002031A (en) 2003-02-25
JP2003535029A (ja) 2003-11-25
DE60036723T2 (de) 2008-07-17
SI20852A (sl) 2002-10-31
CA2382580C (en) 2009-05-19
KR100864547B1 (ko) 2008-10-20
KR20080066095A (ko) 2008-07-15
BG65817B1 (bg) 2010-01-29
SI20852B (sl) 2009-06-30
CZ2002704A3 (cs) 2003-02-12
MXPA02002191A (es) 2002-09-30
PT1229906E (pt) 2008-01-18
LT5034B (lt) 2003-07-25
BG106442A (bg) 2002-09-30
SK287192B6 (sk) 2010-02-08
NO20020999D0 (no) 2002-02-28
PL353930A1 (en) 2003-12-15
EE05172B1 (et) 2009-06-15
EE200200104A (et) 2003-04-15
WO2001015679A2 (en) 2001-03-08
KR20070058023A (ko) 2007-06-07
AR025457A1 (es) 2002-11-27
EP1229906B1 (en) 2007-10-10
EA200200282A1 (ru) 2002-10-31
DE60036723D1 (de) 2007-11-22
NO20020999L (no) 2002-03-14
DK1229906T3 (da) 2008-02-11
MEP13808A (en) 2010-06-10
BR0014161A (pt) 2002-05-21
KR100755109B1 (ko) 2007-09-04
EP1229906A2 (en) 2002-08-14
AU6946600A (en) 2001-03-26
PE20010578A1 (es) 2001-06-04
HRP20020267A2 (en) 2004-04-30
RO122179B1 (ro) 2009-02-27

Similar Documents

Publication Publication Date Title
AU703064B2 (en) Means and method for hormonal contraception and/or acne treatment
DK0792152T3 (da) Fremgangsmåder til svangerskabsforebyggelse
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
CA2182183A1 (en) Treatment of ovarian estrogen dependent conditions
DE69316747D1 (de) Verhuetungsverfahren mittels kompetitive progestronantagonisten und aehnliche neue verbindungen
BG101553A (en) Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives
WO2004000801A3 (en) Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
DK1488784T3 (da) Svangerskabsforebyggende implantat til mænd
CA2467237A1 (en) Method of preventing or treating benign gynaecological disorders
EP1079790A4 (en) BROAD SPECTRUM MICROBICIDE AND GERMICIDE COMPOSITIONS, DEVICES AND METHODS
YU14002A (sh) Mezoprogestini (progesteron receptor modulatori) za lečenje i prevenciju benignih hormonskih ginekoloških poremećaja
WO1994008613A3 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy
WO2001064236A3 (en) METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
YU13902A (sh) Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene
BG102682A (en) System for the release of contraceptives having bactericidal and/or antiviral effect
EA200200285A1 (ru) Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента композиций для заместительной гормональной терапии (згт)
Batioglu et al. The use of GnRH agonists in the treatment of endometriomas with or without drainage
WO2006042561A2 (en) Intrauterine contraceptive system with copper and progesterone
陶晓靖 et al. Determination of the concentration of estrogen, progestin and androgen cytosol receptors in human uterine tissues
CA2219641A1 (en) Diagnostic composition